Scilex vs Tonix Pharmaceuticals
SCLX and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SCLX and TNXP compare
Tonix Pharmaceuticals is the larger company, worth 4.9 times as much as Scilex ($66.4M against $13.7M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus −28.5% for Scilex).
Tonix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −420% compared with −1470% at Scilex.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SCLX | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $13.7M | $66.4M |
| Share price | $1.61 | $3.87 |
| Change, 1 year | −91.4% | −77.0% |
| Change, 5 years | −99.5% | −100.0% |
| Beta (5Y) | 0.82 | 2.06 |
| Employees | 34 | 142 |
| StockData Score | ||
| Total score | 1 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 1.5× |
| P/B | – | 0.3× |
| FCF yield | – | −256% |
| Fair value | – | $18.90 |
| Margin of safety | – | 79.5% |
| Growth | ||
| Revenue growth (TTM) | −28.5% | 318% (better) |
| Revenue growth, 5Y average | 5.1% | – |
| Profitability | ||
| Gross margin | 161% (better) | 89.3% |
| Operating margin | −1136% | −436% (better) |
| Net margin | −1470% | −420% (better) |
| FCF margin | – | −395% |
| Return on equity | – | −84.1% |
| Return on invested capital | – | −388% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −22.2× | – |
| Current ratio | 0.07 | 4.57 (better) |
| Altman Z-score | −12.74 | −6.42 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −224% |
| Shareholder yield | 0.00% (better) | −224% |
| Ownership | ||
| Held by institutions | 9.8% | 54.6% |
| Held by insiders | – | 0.24% |
| Insider net buying, 12 months | −$12.8M | $459K (better) |
| Short interest, % of float | – | 19.4% |
Go deeper
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.